Is there a role for warfarin or aspirin therapy in heart failure?

✍ Scribed by Syed M. Jafri; John Cleland; Barry Massie

• Publisher: Springer
• Year: 1997
• Tongue: English
• Weight: 597 KB
• Volume: 1
• Category: Article
• ISSN: 1382-4147
• DOI: 10.1007/bf00127408

✦ Synopsis

Despite recent advances in pharmacologic therapy of heart failure, mortality remains high. There is growing evidence that thromboembolic events may contribute to these events. There is evidence for platelet activation, hypercoagulability and endothelial dysfunction in heart failure. The incidence of overt thromboembolism in heart failure is low. Ischemic events are a frequent prelude to heart failure. Thus, subclinical embolism and ischemic events may be contributing factors to the morbidity and mortality in heart failure patients. The role of antithrombotic therapy with warfarin or aspirin needs to be systematically investigated to determine if such therapy can reduce mortality in heart failure. Such information is particularly essential because non-randomized data have raised the possibility that aspirin may interfere with the beneficial effects of angiotensin converting enzyme inhibitors. This review summarizes available data on warfarin and aspirin therapy in heart failure.